Sugi Predict

Sugi Predict / Targets / KCNJ1

KCNJ1

ATP-sensitive inward rectifier potassium channel 1 · P48048 · KCNJ1 on Sugi Atlas →

28,900 patent compounds predicted against KCNJ1, 16,976 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL287029 SCHEMBL287029 1.00 20/20
SCHEMBL299426 SCHEMBL299426 0.89 20/20
SCHEMBL300137 SCHEMBL300137 0.84 20/20
SCHEMBL286522 SCHEMBL286522 0.84 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL298335) 0.82 20/20
SCHEMBL298576 SCHEMBL298576 0.80 20/20
SCHEMBL298643 SCHEMBL298643 0.80 20/20
SCHEMBL287211 SCHEMBL287211 0.79 20/20
SCHEMBL300381 SCHEMBL300381 0.78 20/20
SCHEMBL287030 SCHEMBL287030 0.76 20/20
SCHEMBL296663 SCHEMBL296663 0.76 20/20
SCHEMBL286569 SCHEMBL286569 0.73 20/20
SCHEMBL286731 SCHEMBL286731 0.71 20/20
SCHEMBL299680 SCHEMBL299680 0.71 20/20
SCHEMBL297201 SCHEMBL297201 0.70 20/20
SCHEMBL300075 SCHEMBL300075 0.68 20/20
SCHEMBL299828 SCHEMBL299828 0.68 20/20
SCHEMBL298583 SCHEMBL298583 0.64 20/20
SCHEMBL286508 SCHEMBL286508 0.64 20/20
SCHEMBL286733 SCHEMBL286733 0.62 20/20

Clinical trials — most relevant to KCNJ1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes PHASE4COMPLETED
Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR) PHASE4UNKNOWN
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study PHASE4COMPLETED
Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes PHASE4UNKNOWN
Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels PHASE3COMPLETED
Renal Transplantation and Inhaled Anesthetic Sevoflurane (SEVOREIN) PHASE3COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients PHASE2COMPLETED
Sandostatine® LP and Hyperinsulinism PHASE2COMPLETED
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus PHASE2COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK PHASE1COMPLETED
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet PHASE1NOT_YET_RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Characteristics of Andersen-Tawil Syndrome nanCOMPLETED
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development nanCOMPLETED
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome nanRECRUITING
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism nanCOMPLETED
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) nanUNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk nanCOMPLETED
Feasibility of Improving Risk Stratification in Brugada Syndrome nanCOMPLETED
Qatar Cardiovascular Biorepository of AF Patients nanUNKNOWN
Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM) nanCOMPLETED
Gene Study for Infantile Onset Diabetes nanUNKNOWN
Genetic Study for Infantile Onset Diabetes Mellitus nanUNKNOWN
A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China nanCOMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia nanUNKNOWN
The Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
Role of KATP Channel Loss in Type 2 Diabetes nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a KCNJ1 binder may also engage these)

ProteinNameSimilarity
O88335 — 0.995 O88335 →
P35560 — 0.994 P35560 →
Q99712 — 0.990 Q99712 →
O88932 — 0.989 O88932 →
O70339 — 0.988 O70339 →
Q91ZF1 — 0.982 Q91ZF1 →
Q9JM63 — 0.981 Q9JM63 →
P49655 — 0.979 P49655 →
P78508 — 0.977 P78508 →
P48545 — 0.971 P48545 →
F1MYR9 — 0.970 F1MYR9 →
P48548 — 0.969 P48548 →
KCNJ5 G protein-activated inward rectifier potassium channel 4 0.968 landscape →
O02670 — 0.967 O02670 →
P48542 — 0.960 P48542 →
P49658 — 0.960 P49658 →
KCNJ6 G protein-activated inward rectifier potassium channel 2 0.960 landscape →
Q5NVJ6 — 0.959 Q5NVJ6 →
P48550 — 0.957 P48550 →
F1NHE9 — 0.953 F1NHE9 →
Q4TZY1 — 0.953 Q4TZY1 →
TRPM8 Transient receptor potential cation channel subfamily M member 8 0.950 landscape →
Q64198 — 0.950 Q64198 →
P52190 — 0.949 P52190 →
Q64273 — 0.949 Q64273 →
P35561 — 0.949 P35561 →
P52189 — 0.949 P52189 →
P49656 — 0.948 P49656 →
O19182 — 0.948 O19182 →
Q8R455 — 0.948 Q8R455 →